Marking Shift in Company Strategy, Sigma-Aldrich Teams With BU, NHLBI on Biomarker Validation

The five-year collaboration looking at protein biomarkers associated with atherosclerotic cardiovascular disease stems from the company's desire to "participate more closely in discovery projects," said an official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories